VTE Acute Prophylaxis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of acute prophylaxis for venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the VTE prophylaxis-eligible hospitalization rates for each country, as well as the annualized number of hospitalizations projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s acute prophylaxis for VTE forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect VTE prophylaxis-eligible hospitalization rates over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides 20 years of forecast data for the following populations:
- Surgical and non-surgical hospitalizations eligible for VTE acute prophylaxis.
- Orthopedic surgery hospitalizations eligible for VTE acute prophylaxis.
- Non-orthopedic surgery hospitalizations eligible for VTE acute prophylaxis.
- Non-surgical hospitalizations eligible for VTE acute prophylaxis.
- Hip and knee arthroplasty hospitalizations eligible for VTE acute prophylaxis.
- Other orthopedic surgery hospitalizations eligible for VTE acute prophylaxis.
Note: Coverage may vary by country.
